PRISM Weight Loss Index Leader LEXX Soars 24% on Positive DehydraTECH-Processed Rybelsus® Study Results
Lexaria Bioscience Corp. (NASDAQ: LEXX), today’s standout in the PRISM Weight Loss Index, saw its shares surge 24% following the announcement of promising results from its second human pilot study, GLP-1-H24-2. The study highlighted the benefits of DehydraTECH-processed Rybelsus® capsules, designed to enhance the delivery of the GLP-1 drug semaglutide.
Key Highlights:
- No Adverse Events: None of the nine participants who took the DehydraTECH-processed Rybelsus® capsules experienced any adverse events, compared to six out of nine participants who reported mild adverse events with standard Rybelsus® tablets.
- Improved Tolerability: The study confirmed that DehydraTECH-processed Rybelsus® capsules were better tolerated than commercially available Rybelsus® tablets, which are associated with gastrointestinal issues like nausea and diarrhea.
- Innovative Delivery Methods: The study also tested a new in-mouth dissolvable tablet format for DehydraTECH-processed Rybelsus®, which showed promise in delivering the drug through sublingual and buccal absorption.
Recent findings from the same study indicated a trend toward higher overall absorption of semaglutide under fed conditions with DehydraTECH-processed Rybelsus® capsules, despite the usual reduction in absorption with food. Lexaria continues to advance its 2024 GLP-1 experimental program, including the finalization of an ongoing animal study and preparations for an upcoming 12-week chronic human study focused on fasted dosing conditions.
